SENSEX NIFTY

Religare Capital Markets

Aug 21, 2014 at 15:35 | Source: CNBC-TV18
Arvind Bothra picks Aurobindo Pharma as his favourite bet among midcaps and Sun Pharma and Lupin among large caps.
Aug 21, 2014 at 15:34 | Source: CNBC-TV18
Arvind Bothra, VP - Institutional Research at Religare Capital Markets is of the view that one may hold Ipca Laboratories.
Aug 21, 2014 at 15:20 | Source: CNBC-TV18
Watch the interview of Hemen Kapadia of KR Choksey Securities and Ashu Madan of Religare Securities with Sumaira Abidi & Nigel D'Souza on CNBC-TV18, in which they shared their reading and outlook on market and specific stocks.
Aug 21, 2014 at 15:09 | Source: CNBC-TV18
Arvind Bothra, VP - Institutional Research at Religare Capital Markets recommemds buying Aurobindo Pharma with a target of Rs 930.
Aug 20, 2014 at 18:25 | Source: CNBC-TV18
In an interview with CNBC-TV18, Prakash Diwan of Altamount Capital Management and Mehraboon Irani of Nirmal Bang Securities discuss stock specific bets and share their outlook on where the market is headed hereon.
Aug 20, 2014 at 15:43 | Source: PTI
Unlike capital markets regulator SEBI, FMC is not an autonomous body. The government is in the process of strengthening the FMC, especially after the Rs 5,600 crore payment scam surfaced at National Spot Exchange Ltd (NSEL).
Aug 20, 2014 at 13:00 | Source: CNBC-TV18
According to Vikas Khemani of Edelweiss Financial Services India is an attractive market on all parameters and will continue to see FII flows.
Aug 20, 2014 at 12:25 | Source: CNBC-TV18
There have been outflows seen from Russian funds to China and India. Even European equity funds are seeing outflows for the last 7-8 weeks.
Aug 20, 2014 at 11:47 | Source: Moneycontrol.com
Arihant capital markets has recommended hold rating on Tata Steel with a target price of Rs 561, in its research report dated August 19, 2014.
Aug 20, 2014 at 08:33 | Source: Moneycontrol.com
Dolat Capital Market Ltd. bought 3,41,66,970 shares of Dolat Investments at Rs 2.27 on the BSE
Messages on Religare Capital Markets »

Web Messenger

Platinum Member

234150 Followers

Indian indices  

Source:NDTV Profit - 2:30 p.m. Tirthankar Patnaik of Religare Capital Markets says that Nifty has could run up by another 100-150 points before the fundamentals catch up. (Track stocks). All the sectoral indices, except the pharma, are trading higher. Gail India, Tech

4.55 PM Mar 6th

cleverman

Platinum Member

91 Followers

Ranbaxy Labs  

also the stock will have a downside of around 10-15 per cent from these levels. We recommend a sell on the stock," adds Nangra. Arvind Bothra, Vice President, institutional research, Religare Capital Markets, says, "we expect significant negative impact on stock price following this news and reiterate

8.15 PM Jan 24th

BSE/NSE Announcer

Platinum Member

3916 Followers

Crompton Greave  

"). This Advertisement should be read in conjunction with, and in continuation of, the Public Announcement (PA") published on July 04, 2013 and corrigenda to the PA published on July 16, 2013 and November 09,2013 to the shareholders of Crompton Greaves Limited ("Target Company")Religare Capital Markets Ltd

5.45 PM Jan 16th

Web Messenger

Platinum Member

234150 Followers

Ipca Labs  

Source:Economic Times - In a chat with ET Now, Dr Tirthankar Patnaik, Director, Strategist-Institutional Research, Religare Capital Markets Limited, shares his views on pharma space. ET Now: On the entire pharma space, do you think that can still continue to be the big bet into 2014 given

3.29 PM Dec 31st 2013

Web Messenger

Platinum Member

234150 Followers

Glenmark  

Source:Economic Times - In a chat with ET Now, Dr Tirthankar Patnaik, Director, Strategist-Institutional Research, Religare Capital Markets Limited, shares his views on pharma space. ET Now: On the entire pharma space, do you think that can still continue to be the big bet into 2014 given

3.29 PM Dec 31st 2013

Web Messenger

Platinum Member

234150 Followers

News Now  

Source:Economic Times - In a chat with ET Now, Dr Tirthankar Patnaik, Director, Strategist-Institutional Research, Religare Capital Markets Limited, shares his views on market movement in 2014. ET Now: Last day of 2013, how does that really set stage for what your outlook is in the initial part

3.29 PM Dec 31st 2013

Web Messenger

Platinum Member

234150 Followers

Infosys  

Source:Economic Times - In a chat with ET Now, Dr Tirthankar Patnaik, Director, Strategist-Institutional Research, Religare Capital Markets Limited, shares his views on Infosys. ET Now: What makes you bullish on Infosys? Dr Tirthankar Patnaik: We are positive on the whole IT sector and therefore

3.25 PM Dec 31st 2013

DLF  

The central bank will hike repo rate, or the rate at which banks borrow from the central bank (Reserve Bank of India), by a total of 50 basis points (bps) till FY14-end, believes Tirthankar Patnaik, executive vice president- institutional sales, Religare Capital Markets. So it will sock to real

11.52 AM Oct 25th 2013

Infosys  

IT space good buy, Infosys and Tech Mahindra top picks: Gautam Trivedi, MD & Head of Equities, Religare Capital Markets Ltd

2.47 PM Oct 23rd 2013

Infosys  

IT space good buy, Infosys and Tech Mahindra top picks: Gautam Trivedi, MD & Head of Equities, Religare Capital Markets Ltd

2.46 PM Oct 23rd 2013

News across the web »
Jul 08, 2014 at 07:59 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.